EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China.

Autor:	Chen, L.1 (AUTHOR), Tan, B.2 (AUTHOR), Gao, X.3 (AUTHOR), Zhou, K.4 (AUTHOR), Zhao, J.3 (AUTHOR), Xuan, J.5 (AUTHOR)
Zdroj:	Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS181-S182. 2p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect